| |
|
FOUNDER
Sharon L. Monsky, 1953-2002
BOARD OF DIRECTORS
Luke Evnin, PhD, Chairman
Nancy H. Bechtle
Ronald J. Carminati
Dana Delany
Susan Feniger
Bob Saget
Deann Wright
Caryn Zucker
SCIENTIFIC ADVISORY
BOARD
Bruce Alberts, PhD
National Academy of Sciences
David Botstein, PhD
Princeton University
Shaun R. Coughlin, MD, PhD
UC San Francisco
Susan Desmond-Hellman, MD
Genentech
Regis B. Kelly, PhD
UC San Francisco
Henry Metzger, MD
National Institutes of Health
Antony Rosen, MD
Johns Hopkins University
William J. Rutter, PhD
Synergenics, LLC
Bruce U. Wintroub, MD
UC San Francisco
George Yancopoulos, MD, PhD
Regeneron Pharmaceuticals
|
|
|
|
| |
| |
| |
| |
|
|
 |
|
 |
| Cool Comedy — Hot Cuisine Benefit Raises Scleroderma Awareness and More Than $750,000 for Scleroderma Research. |
Los Angeles, CA Wednesday, April 16, 2008Event host and Board Member Bob Saget along with comedians Bill Bellamy, Adam Carolla, Jeff Ross, Sarah Silverman and Grammy® Award winning musical guest John Mayer put on an incredible show for more than 500 guests at the Four Seasons Beverly Wilshire. In total, $757,000 was raised to support the SRF research programs. Click here to see local Los Angeles news station KCAL 9 coverage of the event.
Thank you to culinary superstars Susan Feniger (also a Board Member) and Mary Sue Milliken for providing the Hot Cuisine. The SRF gratefully acknowledges presenting sponsor Actelion Pharmaceuticals and all those who generously supported the event.

|
|
 |
| SRF News & Events: |
| 2007 Annual Report
The Scleroderma Research Foundation is
pleased to make its 2007 Annual Report available
for download as an Adobe PDF file. Included
are the Foundation’s 2007 achievements,
financial information, donor and tribute
listings and compelling stories of courage
and commitment from scleroderma patients,
researchers, advisors and volunteers. Please click
here to download the entire 48-page
document. (Note: This is a large file and
may take several minutes to download depending
upon the speed of your Internet connection.) |
 |
|
|
 |
Research Funding Levels
The Scleroderma Research Foundation (SRF)
has become the nation’s largest private
investor in scleroderma research, raising
more than $22,000,000—with every dollar
coming from charitable gifts from generous
individuals, corporations and foundations.
In 2007, the SRF has provided more than $1,085,000
in direct research grants. Unlike university
and medical foundations restricted to one
institution, the SRF actively searches out
the most promising researchers and laboratories
aimed at helping scleroderma patients around
the world. We are now funding research at
Johns Hopkins, Harvard, Stanford, and Dartmouth;
and helping the University of Washington launch
a new Puget-Sound based research program. A list of funded research is described in the 2007 Annual Report. To make a contribution, please click here. |
|
| |
There is currently no cure for scleroderma but,
in many cases, it can be managed.
|
About us:
The Scleroderma Research Foundation is a 501(c)(3) nonprofit organization whose mission is to find a cure for scleroderma by funding and facilitating the most promising, highest quality research and by placing the disease and the need for a cure in the public eye. Information provided by the SRF should not be considered medical advice, nor is it intended to replace consultation with a qualified physician. The SRF does not evaluate, endorse or recommend any particular medications, products, equipment or treatments. Scleroderma varies substantially from one patient to another, and treatment must be tailored by a physician for each individual case. |
|
 |